UPDATE: Wells Fargo Reinstates Merck (MRK) at Overweight

Wells Fargo analyst Mohit Bansal reinstates coverage on Merck (NYSE: MRK) with a Overweight rating and a price target of $90.00.

The analyst comments "Keytruda growth underappreciated as we see $2B upside potential to consensus by 2025. Street is also ignoring MRK's lifecycle management approach for Keytruda LOE. Readouts in 2023-26 should expand multiple. Business development underappreciated."

For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.

Shares of Merck closed at $72.28 yesterday.

You May Also Be Interested In

• Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
• Old Dominion Freight Line (ODFL) PT Raised to $233 at TD Cowen
• UBS Double Upgrades China Resources Power Holdings (836:HK) (CRPJY) to Buy